PE
REGN icon

Point72 Europe’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 Europe’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$26.9M Buy
47,908
+18,661
+64% +$10.6M 1.32% 14
2025
Q2 		$15.4M Buy
+29,247
New +$16.3M 0.59% 43
2024
Q3 		– Sell
-935
Closed -$983K – 174
2024
Q2 		$983K Buy
+935
New +$906K 0.08% 123

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Europe's REGN Position: Q3 2025 in Review

Point72 Europe increased its Regeneron Pharmaceuticals (REGN) stake by 64% in Q3 2025, buying an estimated $10.6M and bringing the position to 47,908 shares worth $26.9M. The position accounts for 1.32% of the portfolio, ranked #14.

Point72 Europe first reported a position in REGN in Q2 2024 and has held it in 3 quarters since. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Point72 Europe held 47,908 shares of Regeneron Pharmaceuticals worth $26.9M as of Q3 2025.
  • Point72 Europe bought 18,661 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $10.6M.
  • Regeneron Pharmaceuticals made up 1.32% of Point72 Europe's portfolio in Q3 2025, its #14 holding.
  • Point72 Europe first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.